| Description |
1 online resource (230 pages) |
| Contents |
Cover; Title Page; Copyright; Contents; List of contributors; Acknowledgements; Introduction; About the companion website; Chapter 1 Epidermal growth factor receptor family; 1.1 ErbB receptors and their structure; 1.2 ErbB ligands; 1.2.1 Ligand production; 1.2.2 Effects of ligand binding to receptors; 1.3 Downstream signalling molecules and events; 1.4 Signalling regulation; 1.4.1 Regulation of phosphorylation events; 1.4.2 Internalisation of receptors; 1.5 Dysregulation of signalling in cancer; 1.5.1 Receptor over-expression; 1.5.2 Activating mutations; 1.5.3 Altered cellular localisation |
|
1.5.4 Changes in ligand levels1.5.5 Changes in adaptor protein levels; 1.6 Therapeutic opportunities; 1.6.1 Current strategies; 1.6.2 Future strategies; References; Chapter 2 Insulin and the insulin-like growth factor (IGF) family; 2.1 Receptors; 2.2 Ligands; 2.2.1 Types of ligands; 2.2.2 Ligand binding affinities; 2.2.3 Insulin growth factor binding proteins (IGFBPs); 2.3 Downstream signalling molecules and events; 2.4 Dysregulation of signalling in cancer; 2.4.1 Over-expression and activation of receptors; 2.5 Therapeutic opportunities; 2.5.1 Targeting receptors; 2.5.2 Targeting ligands |
|
3.6.2 Anti-sense oligonucleotides3.6.3 Small molecule inhibitors; 3.6.4 Signalling pathway inhibitors; References; Chapter 4 Wnt signalling; 4.1 Introduction and overview; 4.2 The ligands: Wnt proteins, their modification and secretion; 4.3 The receptors: Frizzleds and LRPs, multiple receptors and combinations; 4.4 Regulation of signalling; 4.4.1 Extracellular Wnt antagonists: turning the signalling off at the source; 4.4.2 Intracellular regulation; 4.5 When good signalling goes bad: Wnt signalling in diseases; 4.6 Taming the beast: drugs and small molecule inhibitors targeting Wnt signalling |
|
4.7 Conclusion and perspectivesReferences; Chapter 5 Mammalian target of rapamycin (mTOR) signalling; 5.1 Discovery of mTOR; 5.2 mTOR complexes; 5.2.1 mTORC1; 5.2.2 mTORC2; 5.2.3 Complexes Upstream of mTOR; 5.2.4 Downstream signalling effectors; 5.3 mTOR dysregulation in disease; 5.3.1 Dysregulation of mTOR in cancers; 5.3.2 Dysregulation of mTOR signalling in gynaecological malignancies; 5.4 Therapeutic opportunities; 5.4.1 Current treatments; 5.4.2 Future opportunities; References; Chapter 6 c-Met receptor signalling; 6.1 Historical context -- identification of the MET gene |
| Summary |
A focused, accessible introduction to this key aspect of cancer biology. It covers the individual cell signalling pathways that are known to be involved in cancer development, and, most important, includes the cross- interactions between the pathways together with the current therapeutic approaches. This is a 'must-have' for advanced undergraduate and postgraduate students studying and researching within the field of cancer biology |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record |
| Subject |
Cancer -- Molecular aspects.
|
|
Carcinogenesis.
|
|
Carcinogenesis
|
|
Cancer -- Molecular aspects
|
|
Carcinogenesis
|
| Form |
Electronic book
|
| ISBN |
9781118527832 |
|
1118527836 |
|
